Chyme Reinfusion Restores the Regulatory Bile Salt-FGF19 Axis in Patients With Intestinal Failure

Kiran V K Koelfat, Denis Picot, Xinwei Chang, Mireille Desille-Dugast, Hans M van Eijk, Sander M J van Kuijk, Martin Lenicek, Sabrina Layec, Marie Carsin, Laurence Dussaulx, Eloi Seynhaeve, Florence Trivin, Laurence Lacaze, Ronan Thibault, Frank G Schaap, Steven W M Olde Damink, Kiran V K Koelfat, Denis Picot, Xinwei Chang, Mireille Desille-Dugast, Hans M van Eijk, Sander M J van Kuijk, Martin Lenicek, Sabrina Layec, Marie Carsin, Laurence Dussaulx, Eloi Seynhaeve, Florence Trivin, Laurence Lacaze, Ronan Thibault, Frank G Schaap, Steven W M Olde Damink

Abstract

Background and aims: Automated chyme reinfusion (CR) in patients with intestinal failure (IF) and a temporary double enterostomy (TDE) restores intestinal function and protects against liver injury, but the mechanisms are incompletely understood. The aim was to investigate whether the beneficial effects of CR relate to functional recovery of enterohepatic signaling through the bile salt-FGF19 axis.

Approach and results: Blood samples were collected from 12 patients, 3 days before, at start, and 1, 3, 5, and 7 weeks after CR initiation. Plasma FGF19, total bile salts (TBS), 7-α-hydroxy-4-cholesten-3-one (C4; a marker of bile salt synthesis), citrulline (CIT), bile salt composition, liver tests, and nutritional risk indices were determined. Paired small bowel biopsies prior to CR and after 21 days were taken, and genes related to bile salt homeostasis and enterocyte function were assessed. CR induced an increase in plasma FGF19 and decreased C4 levels, indicating restored regulation of bile salt synthesis through endocrine FGF19 action. TBS remained unaltered during CR. Intestinal farnesoid X receptor was up-regulated after 21 days of CR. Secondary and deconjugated bile salt fractions were increased after CR, reflecting restored microbial metabolism of host bile salts. Furthermore, CIT and albumin levels gradually rose after CR, while abnormal serum liver tests normalized after CR, indicating restored intestinal function, improved nutritional status, and amelioration of liver injury. CR increased gene transcripts related to enterocyte number, carbohydrate handling, and bile salt homeostasis. Finally, the reciprocal FGF19/C4 response after 7 days predicted the plasma CIT time course.

Conclusions: CR in patients with IF-TDE restored bile salt-FGF19 signaling and improved gut-liver function. Beneficial effects of CR are partly mediated by recovery of the bile salt-FGF19 axis and subsequent homeostatic regulation of bile salt synthesis.

© 2021 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.

Figures

FIG. 1
FIG. 1
Dysregulated bile salt synthesis in patients with IF‐TDE prior to CR. (A) Baseline values of TBS, FGF19, and C4 of patients with IF‐TDE (n = 12) compared with controls (n = 12). Note, C4 levels were available for 6 out of 12 healthy volunteers. (B) Correlation between FGF19 and C4 levels in patients with IF‐TDE (blue circles) and controls (black circles). (C) Correlation between jejunal efflux adjusted by weight and FGF19 or C4. Data are depicted as mean ± 95% CI. Differences were evaluated by Mann‐Whitney U test. Correlations were evaluated with Spearman’s (ρ) correlation coefficient. P values are depicted.
FIG. 2
FIG. 2
CR restores homeostatic control of bile salt synthesis within 7 days. Twelve patients with a TDE on PN underwent CR for up to 7 weeks. Blood was sampled at the depicted time points before and after start of CR and analyzed for (A) TBS, FGF19, and C4. (B) Relative change from baseline over time for TBS, FGF19, and C4. (C) Individual changes of TBS, FGF19, and C4 in the first week of CR. (D) Paired small intestinal biopsies were studied (n = 7 patients) at 3 days before CR and 21 days after CR and analyzed for mRNA expression of FXR and genes related to bile salt transport. (E) Proximal jejunal output at start of CR and stomal or fecal output at discharge from the clinic/end of CR were assessed to address intestinal output changes. Data are depicted as mean ± 95% CI. Trends in time were evaluated by ANOVA with repeated measures. mRNA expression and intestinal output differences were evaluated by Wilcoxon matched‐pairs signed ranks sum test. P values are depicted. Asterisks indicate significance levels: *P < 0.05, **P < 0.01, and ***P < 0.001. Abbreviation: ASBT, apical sodium‐dependent bile salt transporter.
FIG. 3
FIG. 3
Alteration of serum bile salt composition after CR initiation. Time course of circulating bile salt composition during CR (n = 12). Graphs show time courses of (A) primary and secondary bile salts, (B) deconjugated and conjugated bile salts, (C) glycine‐conjugated and taurine‐conjugated bile salts, and (D) the sulfated bile salt species GCDCA‐3S. (E) Individual plasma bile salt species. (F) Chyme bile salt composition—molar fraction of individual bile salt species as percentage of total moles of bile salt. (G) Correlation between chyme GCA and GCDCA and plasma levels of FGF19 and C4. Data are depicted as mean ± 95% CI. Trends in time were evaluated by ANOVA with repeated measures. P values are depicted. Asterisks indicate significance levels: *P < 0.05 and **P < 0.01. Abbreviations: BS, bile salt; CA, cholic acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; GDCA, glycodeoxycholic acid; GLCA, glycolithocholic acid; GUDCA, glycoursodeoxycholic acid; LCA, lithocholic acid; TCA, taurocholic acid; TCDCA, taurochenodeoxycholic acid; TDCA, taurodeoxycholic acid; UDCA, ursodeoxycholic acid.
FIG. 4
FIG. 4
CR recovers intestinal absorptive function and ameliorates liver injury. Time course of markers for intestinal absorptive function and nutritional status during CR. (A) CIT values of individual patients at baseline (left panel) with values >20 µmol/L in a dashed box and time course of CIT (right panel). (B) Time course of albumin (dashed line represents normal value). (C) Relative change from baseline over time for CIT and albumin. (D) Paired mRNA expression of epithelium‐specific genes (VIL‐1, SI, CUBN, and OCT) and local inflammation (IL‐6, TNFα, IL1‐β, and IL‐10) at baseline and 3 weeks after CR. (E) Time course of liver injury markers (ALP, GGT, and total bilirubin) and (F) systemic inflammation (CRP). Data are depicted as mean ± 95% CI. Trends in time were evaluated by ANOVA with repeated measures. Gene expression differences were evaluated by Wilcoxon matched‐pairs signed ranks sum test. P values are depicted.
FIG. 5
FIG. 5
The FGF19 response, dependent on the C4 response, after 7 days predicts the plasma course of CIT over time. A linear mixed effects model was constructed to evaluate whether the response of FGF19 and C4 (difference between 7 days and baseline values = Δ) predicts the course of CIT over time. Interaction plot depicting the association between the interaction of ΔFGF19*ΔC4 after 7 days and predicted CIT values over time (from 7 days onward). The ΔFGF19 is depicted on the x‐axis. The y‐axis shows the predicted CIT values. The regression line is shown with 95% CI. R2 and P values are depicted.
FIG. 6
FIG. 6
Schematic summary of the pathophysiology and mechanistic findings before and during CR in patients with IF and a double enterostomy. Abbreviations: ASBT, apical sodium‐dependent bile salt transporter; DCA, deoxycholic acid; GDCA, glycodeoxycholic acid.

References

    1. Pironi L, Arends J, Baxter J, Bozzetti F, Peláez RB, Cuerda C, et al. ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults. Clin Nutr 2015;34:171‐180.
    1. Oterdoom LH, ten Dam SM, de Groot SDW, Arjaans W, van Bodegraven AA, et al. Limited long‐term survival after in‐hospital intestinal failure requiring total parenteral nutrition. Am J Clin Nutr 2014;100:1102‐1107.
    1. Burden S, Hemstock M, Taylor M, Teubner A, Roskell N, MacCulloch A, et al. The impact of home parenteral nutrition on the burden of disease including morbidity, mortality and rate of hospitalisations. Clin Nutr ESPEN 2018;28:222‐227.
    1. Rinsema W, Gouma DJ, von Meyenfeldt MF, Soeters PB. Reinfusion of secretions from high‐output proximal stomas or fistulas. Surg Gynecol Obstet 1988;167:372‐376.
    1. Lévy É, Palmer DL, Frileux P, Parc R, Huguet C, Loygue J, et al. Inhibition of upper gastrointestinal secretions by reinfusion of Succus entericus into the distal small bowel. A clinical study of 30 patients with peritonitis and temporary enterostomy. Ann Surg 1983;198:596‐600.
    1. Picot D, Garin L, Trivin F, Kossovsky MP, Darmaun D, Thibault R, et al. Plasma citrulline is a marker of absorptive small bowel length in patients with transient enterostomy and acute intestinal failure. Clin Nutr 2010;29:235‐242.
    1. Picot D, Layec S, Seynhaeve E, Dussaulx L, Trivin F, Carsin‐Mahe M, et al. Chyme reinfusion in intestinal failure related to temporary double enterostomies and enteroatmospheric fistulas. Nutrients 2020;12:1376.
    1. Inagaki T, Choi M, Moschetta A, Peng LI, Cummins CL, McDonald JG, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005;2:217‐225.
    1. Cai S‐Y, Ouyang X, Chen Y, Soroka CJ, Wang J, Mennone A, et al. Bile acids initiate cholestatic liver injury by triggering a hepatocyte‐specific inflammatory response. JCI Insight 2017;2:e90780.
    1. Pereira‐Fantini PM, Lapthorne S, Joyce SA, Dellios NL, Wilson G, Fouhy F, et al. Altered FXR signalling is associated with bile acid dysmetabolism in short bowel syndrome–associated liver disease. J Hepatol 2014;61:1115‐1125.
    1. Xiao Y‐T, Cao YI, Zhou K‐J, Lu L‐N, Cai W. Altered systemic bile acid homeostasis contributes to liver disease in pediatric patients with intestinal failure. Sci Rep 2016;6:39264.
    1. Koelfat KVK, Visschers RGJ, Hodin C, de Waart DR, van Gemert WG, Cleutjens JPM, et al. FXR agonism protects against liver injury in a rat model of intestinal failure–associated liver disease. J Clin Transl Res 2018;3:318‐327.
    1. Mutanen A, Lohi J, Heikkilä P, Jalanko H, Pakarinen MP. Loss of ileum decreases serum fibroblast growth factor 19 in relation to liver inflammation and fibrosis in pediatric onset intestinal failure. J Hepatol 2015;62:1391‐1397.
    1. Koelfat KVK, Huijbers A, Schaap FG, van Kuijk SMJ, Lenicek M, Soeters MR, et al. Low circulating concentrations of citrulline and FGF19 predict chronic cholestasis and poor survival in adult patients with chronic intestinal failure: development of a Model for End‐Stage Intestinal Failure (MESIF risk score). Am J Clin Nutr 2019;109:1620‐1629.
    1. Walters JRF, Tasleem AM, Omer OS, Brydon WG, Dew T, le Roux CW, et al. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol 2009;7:1189‐1194.
    1. Hirschfield GM, Chazouillères O, Drenth JP, Thorburn D, Harrison SA, Landis CS, et al. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double‐blind, placebo‐controlled phase II trial. J Hepatol 2019;70:483‐493.
    1. Harrison SA, Rinella ME, Abdelmalek MF, Trotter JF, Paredes AH, Arnold HL, et al. NGM282 for treatment of non‐alcoholic steatohepatitis: a multicentre, randomised, double‐blind, placebo‐controlled, phase 2 trial. Lancet 2018;391:1174‐1185.
    1. Picot D, Layec S, Dussaulx L, Trivin F, Thibault R. Chyme reinfusion in patients with intestinal failure due to temporary double enterostomy: a 15‐year prospective cohort in a referral centre. Clin Nutr 2017;36:593‐600.
    1. Aziz EF, Javed F, Pratap B, Musat D, Nader A, Pulimi S, et al. Malnutrition as assessed by nutritional risk index is associated with worse outcome in patients admitted with acute decompensated heart failure: an ACAP‐HF data analysis. Heart Int 2011;6:e2.
    1. Schaap FG, van der Gaag NA, Gouma DJ, Jansen PLM. High expression of the bile salt‐homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 2009;49:1228‐1235.
    1. van Eijk HM, Rooyakkers DR, Deutz NE. Rapid routine determination of amino acids in plasma by high‐performance liquid chromatography with a 2–3 microns Spherisorb ODS II column. J Chromatogr 1993;620:143‐148.
    1. Axelson M, Aly A, Sjovall J. Levels of 7 alpha‐hydroxy‐4‐cholesten‐3‐one in plasma reflect rates of bile acid synthesis in man. FEBS Lett 1988;239:324‐328.
    1. Koelfat KVK, Plummer MP, Schaap FG, Lenicek M, Jansen PLM, Deane AM, et al. Gallbladder dyskinesia is associated with an impaired postprandial fibroblast growth factor 19 response in critically ill patients. Hepatology 2019;70:308‐318.
    1. Ruijter JM, Ramakers C, Hoogaars WMH, Karlen Y, Bakker O, van den Hoff MJB, et al. Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic Acids Res 2009;37:e45.
    1. Eusufzai S, Axelson M, Angelin B, Einarsson K. Serum 7 alpha‐hydroxy‐4‐cholesten‐3‐one concentrations in the evaluation of bile acid malabsorption in patients with diarrhoea: correlation to SeHCAT test. Gut 1993;34:698‐701.
    1. Vergnes L, Lee J, Chin R, Auwerx J, Reue K. Diet1 functions in the FGF15/19 enterohepatic signaling axis to modulate bile acid and lipid levels. Cell Metab 2013;17:916‐928.
    1. Sayin S, Wahlström A, Felin J, Jäntti S, Marschall H‐U, Bamberg K, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro‐beta‐muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013;17:225‐235.
    1. Masubuchi N, Sugihara M, Sugita T, Amano K, Nakano M, Matsuura T, et al. Oxidative stress markers, secondary bile acids and sulfated bile acids classify the clinical liver injury type: promising diagnostic biomarkers for cholestasis. Chem Biol Interact 2016;255:83‐91.
    1. Hofmann A. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 1999;159:2647.
    1. Crenn P, Coudray–Lucas C, Thuillier F, Cynober L, Messing B. Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans. Gastroenterology 2000;119:1496‐1505.
    1. Hirschfield GM, Chazouilleres O, Drenth JP, Thorburn D, Harrison SA, Landis CS, et al. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double‐blind, placebo‐controlled phase II trial. J Hepatol 2019;70:483‐493.
    1. Luo J, Ko B, Elliott M, Zhou M, Lindhout DA, Phung V, et al. A nontumorigenic variant of FGF19 treats cholestatic liver diseases. Sci Transl Med 2014;6:247ra100.
    1. Mayo MJ, Wigg AJ, Leggett BA, Arnold H, Thompson AJ, Weltman M, et al. NGM282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double‐blind, placebo‐controlled trial. Hepatol Commun 2018;2:1037‐1050.
    1. Gadaleta RM, Garcia‐Irigoyen O, Cariello M, Scialpi N, Peres C, Vetrano S, et al. Fibroblast growth factor 19 modulates intestinal microbiota and inflammation in presence of farnesoid X receptor. EBioMedicine 2020;54:102719.
    1. Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen ECL, Renooij W, Murzilli S, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 2011;60:463‐472.
    1. Erlinger S, Dhumeaux D. Mechanisms and control of secretion of bile water and electrolytes. Gastroenterology 1974;66:281‐304.
    1. Walters JRF, Johnston IM, Nolan JD, Vassie C, Pruzanski ME, Shapiro DA, et al. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. Aliment Pharmacol Ther 2015;41:54‐64.
    1. Wilson SD, Schulte WJ, Meade RC. Longevity studies following total gastrectomy in children with the Zollinger‐Ellison syndrome. Arch Surg 1971;103:108‐115.
    1. Zaterka S, Grossman MI. The effect of gastrin and histamine on secretion of bile. Gastroenterology 1966;50:500‐505.
    1. Zhang JH, Nolan JD, Kennie SL, Johnston IM, Dew T, Dixon PH, et al. Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids. Am J Physiol Gastrointest Liver Physiol 2013;304:G940‐G948.
    1. Galman C, Arvidsson I, Angelin B, Rudling M. Monitoring hepatic cholesterol 7alpha‐hydroxylase activity by assay of the stable bile acid intermediate 7alpha‐hydroxy‐4‐cholesten‐3‐one in peripheral blood. J Lipid Res 2003;44:859‐866.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel